VOCLOSPORIN IS EFFECTIVE IN ACHIEVING PROTEINURIA TREATMENT TARGETS IN LUPUS NEPHRITIS DEFINED BY EULAR/ERA RECOMMENDATIONS

被引：1
|
作者：
Anders, H. J. [1 ]
Federico, R. [2 ]
Randhawa, S. [2 ]
Leher, H. [2 ]
机构：
[1] Klinikum Univ Munchen, Med Klin & Poliklin 4, Munich, Germany
[2] Aurinia Pharmaceut Inc, Med Affairs, Victoria, BC, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.210
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0285
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [31] Lupus Nephritis: From Pathogenesis to Targets for Biologic Treatment
    Liu, Yujuan
    Anders, Hans-Joachim
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 224 - 231
  • [32] Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria
    Uchino, A.
    Tsukamoto, H.
    Nakashima, H.
    Yoshizawa, S.
    Furugo, I.
    Mitoma, H.
    Oryoji, K.
    Shimoda, T.
    Niiro, H.
    Tada, Y.
    Yano, T.
    Nonaka, T.
    Oishi, R.
    Akashi, K.
    Horiuchi, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (01) : 6 - 12
  • [33] Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
    Kostopoulou, Myrto
    Fanouriakis, Antonis
    Cheema, Kim
    Boletis, John
    Bertsias, George
    Jayne, David
    Boumpas, Dimitrios T.
    RMD OPEN, 2020, 6 (02):
  • [34] VOCLOSPORIN INHIBITS CALCINEURIN AND T CELL ACTIVATION AT DOSE LEVELS CLINICALLY RELEVANT FOR THE TREATMENT OF LUPUS NEPHRITIS
    Rehaume, Linda M.
    Cross, Jennifer L.
    Hulzinga, Robert B.
    Viel, John J.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S97 - S97
  • [35] Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria
    Fu, LW
    Yang, LY
    Chen, WP
    Lin, CY
    BRITISH JOURNAL OF RHEUMATOLOGY, 1998, 37 (02): : 217 - 221
  • [36] Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria
    Tse, KC
    Li, FK
    Tang, S
    Tang, CSO
    Lai, KN
    Chan, TM
    LUPUS, 2005, 14 (12) : 947 - 952
  • [37] MYCOPHENOLATE MOFETIL: A POTENTIAL TREATMENT FOR REDUCING PROTEINURIA ASSOCIATED WITH MEMBRANOUS LUPUS NEPHRITIS
    Ferro, M. L.
    Karim, M. Y.
    Abbs, I. C.
    D'Cruz, D. P.
    Khamashta, M. A.
    Hughes, G. R. V.
    RHEUMATOLOGY, 2003, 42 : 79 - 79
  • [38] Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment
    Touma, Zahi
    Urowitz, Murray B.
    Ibanez, Dominique
    Gladman, Dafna D.
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (04) : 688 - 697
  • [39] The effective use of Mycophenolate mofetil in the treatment of lupus nephritis.
    Kingdon, EJ
    Psimenou, E
    Sweny, P
    Burns, A
    KIDNEY INTERNATIONAL, 1999, 55 (06) : 2563 - 2563
  • [40] Tacrolimus is effective for induction treatment of diffuse proliferative lupus nephritis
    Li, LS
    Chen, Q
    Hu, WX
    Chen, X
    Chen, HP
    Liu, ZH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 38A - 38A
12345